Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study

Colombo, Chiara, Miceli, Rosalba, Lazar, Alexander J., Perrone, Federica, Pollock, Raphael E., Le Cesne, Axel, Hartgrink, Henk H., Cleton‐Jansen, Anne‐Marie, Domont, Julien, Bovée, Judith V. M. G., Bonvalot, Sylvie, Lev, Dina, Gronchi, Alessandro · 2013 · Cancer

Abstract

BACKGROUND: A role for the serine to phenylalanine substitution at codon 45 (the S45F mutation) in the catenin (cadherin‐associated protein) β‐1 (CTNNB1) gene as a molecular predictor of local recurrence in patients with primary, sporadic desmoid tumor (DT) has been reported. To confirm the previous data, the authors evaluated the correlation between CTNNB1 mutation type and local recurrence in this multi‐institutional, retrospective study. METHODS: Patients with primary, sporadic DT who underwent macroscopic complete surgical resection were included. Recurrence‐free survival (RFS) analyses were conducted using the Kaplan‐Meier method and log‐rank tests to compare strata. RESULTS: In total, 179 patients were identified, including 65% females and 35% males (median age, 39 years; median tumor size, 7 cm). Most DTs were located in the abdominal/chest wall (42%) followed by extra‐abdominal sites (40%) and intra‐abdominal sites (18%). All patients underwent either R0 resection (62%) or R1 resection (38%), and most underwent surgery alone (80%). The tyrosine to alanine substitution at codon 41 (T41A) was the most frequent mutation (45%), but the S45F mutation was more prevalent in extra‐abdominal DTs compared with other sites (P < .001). At a median follow‐up of 50 months, 86% of patients remained alive without disease. The estimated 3‐year and 5‐year RFS rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation; 0.91 and 0.91, respectively, for patients who had wild‐type tumors; and 0.70 and 0.66, respectively, for all others (P < .001). A similar trend was observed for patients who underwent surgery alone (P < .001). On multivariable analysis, mutation remained the only factor that was prognostic for local recurrence. CONCLUSIONS: This series confirmed that primary, completely resected, sporadic DTs with the S45F mutation have a greater tendency for local recurrence. With increasing implementation of “watchful‐waiting” for DT management, it will be important to determine whether mutation type predicts outcome for these patients. Cancer 2013;119:3692–3702. © 2013 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28271

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 184

Metadata

Authors
Colombo, C., Miceli, R., Lazar, A. J., Perrone, F., Pollock, R. E., Le Cesne, A., Hartgrink, H. H., Cleton‐Jansen, A., Domont, J., Bovée, J. V. M. G., Bonvalot, S., Lev, D., & Gronchi, A.
Venue
Cancer
Publisher
Wiley
Published
2013-07-31
Volume
119
Issue
20
Pages
3696-3702
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1602160127
Cited by
184
References
1
FWCI
11.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. https://app.cochat.ai/papers/10.1002/cncr.28271
The paper
Colombo, C., Miceli, R., Lazar, A. J., Perrone, F., Pollock, R. E., Le Cesne, A., Hartgrink, H. H., Cleton‐Jansen, A., Domont, J., Bovée, J. V. M. G., Bonvalot, S., Lev, D., & Gronchi, A. (2013). CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. Cancer. https://doi.org/10.1002/cncr.28271

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.